People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...

The American Diabetes Association has recognized Bonner General Health through the organization's Education Recognition Program. The diabetes self-management education and support service was ...

Aspirus Iron River, Aspirus Ironwood and Aspirus Keweenaw Hospitals were recently awarded the American Diabetes Association Education Recognition Certificate for quality diabetes management education ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

In addition to meeting the primary endpoint of superior A1C reduction, the once-daily oral pill reduced weight by an average ...

Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor’s successful drug trial.

A local organization is swapping bikes for beer taps to raise funds for the 2025 ADA Finger Lakes Tour de Cure.

Community members living with diabetes are taking an active role in combating the diabetes epidemic by participating in the 2025 Tour de Cure.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

We’re trying to get people to see that.” The American Diabetes Association (ADA) concurred, noting that ending DPP and DPPOS runs counter to HHS’ stated goals. Eliminating funding “means ...

Eli Lilly (LLY) announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in ...